Pierre Chelle
University of Waterloo
H-index: 11
North America-Canada
Top articles of Pierre Chelle
Canadian clinical experience on switching from standard half‐life recombinant factor VIII (rFVIII), octocog alfa, to extended half‐life rFVIII, damoctocog alfa pegol, in …
Haemophilia
2024/2/20
OC 24.1 Effect of the Type of F9 Mutation on the Pharmacokinetic Profile of Patients with Hemophilia B Treated with Extended Half-Life FIX Concentrates
Research and Practice in Thrombosis and Haemostasis
2023/10/1
OC 24.2 Estimated Factor VIII Activity Levels at the Time of Bleeding Events in Individuals with Hemophilia a Without Inhibitors
2023/10/1
A personalized limited sampling approach to better estimate terminal half‐life of FVIII concentrates
Journal of Thrombosis and Haemostasis
2022/9/1
Pierre Chelle
H-Index: 7
Alfonso Iorio
H-Index: 47
Revised terminal half‐life of nonacog alfa as derived from extended sampling data: A real‐world study involving 64 haemophilia B patients on nonacog alfa regular prophylaxis
Haemophilia
2022/7
Pierre Chelle
H-Index: 7
Predicting individual changes in terminal half-life after switching to extended half-life concentrates in patients with severe Hemophilia
HemaSphere
2022/4/1
External qualification of the Web‐Accessible Population Pharmacokinetic Service–Hemophilia (WAPPS‐Hemo) models for octocog alfa using real patient data
Research and Practice in Thrombosis and Haemostasis
2021/10/1
Terminal half‐life of FVIII and FIX according to age, blood group and concentrate type: Data from the WAPPS database
Journal of Thrombosis and Haemostasis
2021/8/1
Use of population PK/PD approach to model the thrombin generation assay: assessment in haemophilia A plasma samples spiked by a TFPI antibody
Journal of Pharmacokinetics and Pharmacodynamics
2021/8
Pierre Chelle
H-Index: 7
Comparison of single subject and population‐based pharmacokinetics for optimizing prophylaxis with simoctocog alfa in patients with haemophilia A
Haemophilia
2021/7
Pediatric dose selection for therapeutic proteins
2021/6
Pierre Chelle
H-Index: 7
Patient-specific modelling of blood coagulation
Bulletin of Mathematical Biology
2021/5
Limited sampling strategies for accurate determination of extended half‐life factor VIII pharmacokinetics in severe haemophilia A patients
Haemophilia
2021/5
Pierre Chelle
H-Index: 7
Pharmacokinetic implications of dosing emicizumab based on vial size: A simulation study
Haemophilia
2021/5
A novel, enriched population pharmacokinetic model for recombinant factor VIII-Fc fusion protein concentrate in hemophilia A patients
Thrombosis and haemostasis
2020/5
Development and evaluation of the population pharmacokinetic models for FVIII and FIX concentrates of the WAPPS‐Hemo project
2020/5
Pierre Chelle
H-Index: 7
Alfonso Iorio
H-Index: 47
Multicentre pharmacokinetic evaluation of rFVIII‐Fc (efmoroctocog alfa) in a real life and comparison with non‐extended half‐life FVIII concentrates
Haemophilia
2020/3
Alfonso Iorio
H-Index: 47
Pierre Chelle
H-Index: 7
Clustering of thrombin generation test data using a reduced mathematical model of blood coagulation
Acta Biotheoretica
2020/3
Body mass index best predicts recovery of recombinant factor VIII in underweight to obese patients with severe haemophilia A
Thrombosis and Haemostasis
2020/2
Development and Validation of a Population-Pharmacokinetic Model for Rurioctacog Alfa Pegol (Adynovate®): A Report on Behalf of the WAPPS-Hemo …
medRxiv
2023
